NL-OMON52048撤回不适用
A clinical study to investigate Interferon gamma (IFN*) signature in patients post HSCT and in patients with impaired HSC proliferation pre-transplant - IFNg-study
Swedish Orphan International0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 0 至 99（—）
入选标准
- •The patient must have consented to the use of their clinical data and
- •biological samples for research investigations.
- •In HSCT cohort:
- •- Patients with underlying:
- •I. non-malignant hematological disease (e.g. autoimmune and metabolic
- •disorders, aplastic
- •anemia, Sickle cell anemia, Fanconi anemia, Diamond-blackfan anemia,
- •thalassemia,
- •osteopetrosis, Wiskott-Aldrich syndrome, severe combined immunodeficiency)
- •II. malignant disease with higher risk of GF, i.e. Acute Myeloid Leukemia (AML)
- •Lymphoblastic Leukemia (ALL) with primary induction failure, second partial
- •remission or
- •relapse* Chronic Myeloid Leukemia (CML) in blastic phase (circulating blast or
- •blast above 5%
- •in biopsy)* Non Hodgkin and Hodgkin Lymphoma and multiple myeloma with primary
- •induction failure, second partial remission or relapse, myelodysplastic
- •syndromes (MDS) and
- •myeloproliferative disorders (MPD) with splenomegaly, myelofibrosis with portal
- •hypertension pre-transplant, MDS/MPD overlap syndromes
- •- and who received allogeneic HSCT and are at higher risk of graft failure
- •based on at least one of the following criteria:
- •I. Having received reduced intensity conditioning (RIC) or non myeloablative
- •conditioning (NMA)
- •combined with a non-malignant disease or having received graft from Bone Marrow
- •II. Ex vivo T cell depleted graft
- •III. Graft from mismatched unrelated donor or
- •haploidentical donor
- •IV. Graft from Umbilical Cord Blood (UCB)
- •In the IHSCP cohort:
- •- Patients with IHSCP pre-transplant (e.g. aplastic anemia)
排除标准
- •HLH patients
- •Body weight < 10kg
研究者
相似试验
招募中
1 期
Human recombinant interferon gamma in the treatment of ventilator-acquired pneumonia in ICU patients. IGNORANT studyCTIS2022-502229-16-00Hospices Civils De Lyon132
进行中（未招募）
不适用
A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapysteroid-refractory bronchiolitis obliteransMedDRA version: 13.1Level: PTClassification code 10029888Term: Obliterative bronchiolitisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-022467-36-DEFreistaat Bayern
终止
早期 1 期
Recombinant Interferon Gamma in Treating Patients With Soft Tissue SarcomaMyxoid LiposarcomaRound Cell LiposarcomaSynovial SarcomaNCT01957709Fred Hutchinson Cancer Center8
Unknown
3 期
Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of CandidemiaCandidemiaNCT01270490Radboud University Medical Center20
招募中
不适用
Sleep electroencephalogram (EEG) recordings in interferon-alpha treated hepatitis C patients – Pilot StudyMood side effects of interferon alpha treatmentMood effects of interferon treatment of hepatitis C patientsMental Health - DepressionACTRN12608000526370nited Hospitals Bristol15